AstraZeneca Stock News

AstraZeneca PLC (LSE:AZN) has scored another significant milestone in its cancer treatment programme, securing accelerated approval from the US Food and Drug Administration (FDA) for Datroway, a promising drug aimed at treating advanced lung cancer. According to analysts at Shore Capital, this marks a notable step forward, even though the approval initially targets a smaller patient group than ...

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a Phase 2 trial. The approval was also supported by data from a Phase 3 trial.

AstraZeneca said on Tuesday that U.S. regulators have approved its precision drug Datroway to treat a type of lung cancer, adding that the drugmaker would now pay partner Daiichi Sankyo $45 million in milestone-related considerations.

Die US-Bank JPMorgan hat die Einstufung für Astrazeneca GB0009895292 mit einem Kursziel von 14000 Pence auf "Overweight" belassen.

Shares in AstraZeneca PLC (LSE:AZN), the largest company on the FTSE 100 index, and fellow blue chip GSK PLC (LSE:GSK, NYSE:GSK) were down 1.4% and 1.9% respectively on renewed worries about US drug tariffs. The pharmaceutical pair were a large drag on the London index after US President Donald Trump said tariffs on imported drugs could be imposed “very soon”, echoing comments from two months ago.

Britain could face higher drug costs as part of a deal to stave off future tariffs from Donald Trump, according to a report in the Daily Telegraph. Documents released after a recent trade agreement show the NHS is expected to review its approach to drug pricing in response to US demands.

I highlight 15 dividend-paying stocks from Bloomberg's 50 Companies to Watch that meet my 'safer' criteria: free cash flow yields exceed dividend yields. The top ten dividend focus stocks offer an estimated average net gain of 15.48% by June 2026, with diversified sector representation and generally lower volatility. Five stocks - China Hongqiao, ITV, Vodacom, Subsea 7, and Advanced Info - stan...

AstraZeneca PLC (LSE:AZN) is betting big on AI-enabled drug discovery (and China), agreeing a research collaboration with China's CSPC Pharmaceutical Group that could see the Anglo-Swedish drugmaker pay up to $3.6 billion in milestone payments. The deal focuses on developing new oral treatments for chronic conditions, with both companies contributing to the discovery and development of pre-clin...